Gliprip-MV2 Tablet PR
Gliprip-MV2 Tablet PR
Glimepiride (2mg) + Metformin (500mg) + Voglibose (0.2mg)
Cheaper alternative availability
Already at the Best Price
This medicine doesn't have a cheaper alternative with the same composition. Our health advisors can help you find other savings options based on your prescription.
About This Medicine
Product description & overview
Gliprip-MV2 Tablet PR is a combination oral antihyperglycemic agent containing Glimepiride (2mg), Metformin (500mg), and Voglibose (0.2mg), indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea, enhances pancreatic insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic gluconeogenesis and improves peripheral insulin sensitivity, contributing to better glycemic control. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption from the gastrointestinal tract, minimizing postprandial hyperglycemia. The synergistic action of these agents targets multiple pathophysiological defects in type 2 diabetes, improving both fasting and postprandial blood glucose levels. Gliprip-MV2 Tablet PR is prescribed as an adjunct to diet and exercise when monotherapy or dual therapy has proven insufficient. It is essential to monitor blood glucose regularly to adjust dosage and avoid hypoglycemia. Caution is advised in patients with renal or hepatic impairment, and contraindications include type 1 diabetes, diabetic ketoacidosis, and known hypersensitivity to any component. Common adverse effects may include gastrointestinal disturbances and hypoglycemia. Patient adherence to lifestyle modifications alongside pharmacotherapy enhances therapeutic outcomes. This combination therapy offers a comprehensive approach to glycemic management in type 2 diabetes patients requiring multi-mechanistic intervention.
Active composition
Glimepiride 2 mg
+2 more active ingredients
About Glimepiride
Glimepiride is an oral hypoglycemic agent used to manage blood sugar levels in patients with type 2 diabetes mellitus. It works by stimulating the pancreas to release more insulin, thereby lowering blood glucose levels and preventing the symptoms associated with diabetes. Glimepiride is often prescribed alongside diet and exercise to enhance glycemic control and reduce the risk of diabetes-related complications, such as kidney damage and neuropathy. In summary, Glimepiride is an essential medication for controlling blood sugar levels in type 2 diabetes patients.
How It Works
Glimepiride stimulates insulin secretion from pancreatic beta cells and enhances insulin sensitivity in peripheral tissues, facilitating glucose uptake and lowering blood sugar levels.
All Active Ingredients
Voglibose
Voglibose inhibits intestinal alpha-glucosidases, delaying carbohydrate digestion and absorption, thus lowering postprandial glucose levels.
Metformin
Metformin reduces hepatic glucose production and enhances peripheral insulin sensitivity, lowering blood glucose levels.
Dosage & How to Use
Dosage information not available. Please consult your doctor or pharmacist.
Safety Advice
Important precautions
Side Effect Occurrence
Based on clinical trials and patient reports.
Overall Tolerance
Most patients tolerate well
Common Side Effects
Safety Advice
Alcohol
It is unsafe to consume alcohol with Gliprip-MV2 Tablet PR.
High Risk
Pregnancy
Gliprip-MV2 Tablet PR may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
Medical Advice
Driving
Your ability to drive may be affected if your blood sugar is too low or too high. Do not drive if these symptoms occur.
Exercise Caution
Liver
Gliprip-MV2 Tablet PR should be used with caution in patients with liver disease. Dose adjustment of Gliprip-MV2 Tablet PR may be needed. Please consult your doctor. Gliprip-MV2 Tablet PR is generally started with low dose in patients with mild to moderate liver disease and its use is not recommended in patients with severe liver disease.
Regular Checkup
Breastfeeding
Gliprip-MV2 Tablet PR is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Consult Doctor
Kidney
Gliprip-MV2 Tablet PR is probably unsafe to use in patients with kidney disease and should be avoided. Please consult your doctor. Use of Gliprip-MV2 Tablet PR is, however, not recommended in patients with severe kidney disease.
Regular Checkup
Customer Reviews
0 reviews for Gliprip-MV2 Tablet PR
